CTOR Citius Oncology, Inc.
Healthcare$0.84+1.31%ClosedMarket Cap: $78.1M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.38
P/S
13.92
EV/EBITDA
-1.85
DCF Value
$0.10
FCF Yield
-21.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.1%
Operating Margin
-775.6%
Net Margin
-757.6%
ROE
-99.5%
ROA
-42.2%
ROIC
-103.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $1.7M | 80.3% | $-28.6M | $-26.6M | $— | — |
| Q1 null | $3.9M | 80.0% | $-5.3M | $-5.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-4.7M | $-5.0M | $— | — |
| FY null | $0.00 | NaN% | $-23.5M | $-24.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.9M | $-5.4M | $— | — |
| Q2 null | $0.00 | NaN% | $-7.5M | $-7.7M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.4M | $-6.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-6.7M | $-6.8M | $— | — |
| FY null | $0.00 | NaN% | $-20.6M | $-21.1M | $— | — |
| Q3 null | $0.00 | NaN% | $-4.6M | $-4.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-4.7M | $-4.8M | $— | — |
| Q1 2024 | $0.00 | NaN% | $-4.6M | $-4.7M | $-0.06 | — |